Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Diabetes

Free Subscription Articles published in Br J Ophthalmol Retrieve available abstracts of 19 articles: HTML format

Single Articles

August 2025
1. JOSEPH S, Wang Y, Drinkwater JJ, Jan CL, et al
   Effectiveness of artificial intelligence-based diabetic retinopathy screening in primary care and endocrinology settings in Australia: a pragmatic trial.
   Br J Ophthalmol. 2025 Aug 22:bjo-2025-327447. doi: 10.1136/bjo-2025-327447.
   PubMed     Abstract available
   
   
   July 2025
2. KIM SJ, Gangaputra S, Sheng J, Patel S, et al
   Analysis of 24 pro-inflammatory cytokines in aqueous and serum of 94 patients without diabetes.
   Br J Ophthalmol. 2025 Jul 22:bjo-2025-327421. doi: 10.1136/bjo-2025-327421.
   PubMed     Abstract available
   
   
   
3. HASHIMOTO Y, Hunt AR, Silva R, Witmer A, et al
   Differentiating treatment episodes from gaps in eyes with diabetic macular oedema.
   Br J Ophthalmol. 2025 Jul 1:bjo-2025-327238. doi: 10.1136/bjo-2025-327238.
   PubMed     Abstract available
   
   
   June 2025
4. WU H, Su Z, Pan X, Shao A, et al
   Enhancing diabetic retinopathy query responses: assessing large language model in ophthalmology.
   Br J Ophthalmol. 2025 Jun 30:bjo-2024-325861. doi: 10.1136/bjo-2024-325861.
   PubMed     Abstract available
   
   
   
5. PANDEY PU, Micieli JA, Ong Tone S, Eng KT, et al
   Realistic fundus photograph generation for improving automated disease classification.
   Br J Ophthalmol. 2025;109:791-798.
   PubMed     Abstract available
   
   
   May 2025
6. RUIZ-MEDRANO J, Udaondo Mirete P, Fernandez-Jimenez M, Asencio-Duran M, et al
   Biomarkers of risk of switching to dexamethasone implant for the treatment of diabetic macular oedema in real clinical practice: a multicentric study.
   Br J Ophthalmol. 2025 May 16:bjo-2024-325665. doi: 10.1136/bjo-2024-325665.
   PubMed     Abstract available
   
   
   
7. LIU Z, Huang Y, Jin L, Pan C, et al
   Validation of a self-administered Home ETDRS visual acuity testing (H-ETDRS) for self-monitoring vision changes in retinal diseases.
   Br J Ophthalmol. 2025 May 10:bjo-2024-326283. doi: 10.1136/bjo-2024-326283.
   PubMed     Abstract available
   
   
   March 2025
8. LEE WA, Shao SC, Hsieh MH, Liao TC, et al
   Adverse renal events between ranibizumab and aflibercept in patients with diabetic macular oedema in Taiwan: a comparative cohort study.
   Br J Ophthalmol. 2025 Mar 27:bjo-2024-325509. doi: 10.1136/bjo-2024-325509.
   PubMed     Abstract available
   
   
   
9. ZHANG W, Cheng S, Gu X, Liu X, et al
   Simultaneous inhibition of fibroblast growth factor-2 and vascular endothelial growth factor-a with RC28-E in diabetic macular edema: a phase 2 randomised trial.
   Br J Ophthalmol. 2025 Mar 23:bjo-2024-326006. doi: 10.1136/bjo-2024-326006.
   PubMed     Abstract available
   
   
   February 2025
10. DANIELI L, Midena G, Frizziero L, Midena E, et al
    Disorganisation of inner retinal layers in diabetic macular oedema: is it time to standardise this OCT biomarker?
    Br J Ophthalmol. 2025 Feb 27:bjo-2024-326843. doi: 10.1136/bjo-2024-326843.
    PubMed     Abstract available
    
    
    
11. CAO J, Su T, Chen S, Du Z, et al
    Evaluating lipid-lowering drug targets for full-course diabetic retinopathy.
    Br J Ophthalmol. 2025 Feb 3:bjo-2024-325771. doi: 10.1136/bjo-2024-325771.
    PubMed     Abstract available
    
    
    November 2024
12. PARIS A, Volpe G, Perruchoud-Ader K, Casanova A, et al
    Short-term intraocular pressure changes after intravitreal aflibercept 2 mg, aflibercept 8 mg and faricimab: a prospective, comparative study.
    Br J Ophthalmol. 2024 Nov 12:bjo-2024-326053. doi: 10.1136/bjo-2024-326053.
    PubMed     Abstract available
    
    
    August 2024
13. ZHONG X, Yang S, Zhu Z, Li H, et al
    Trajectories of choriocapillaris perfusion in healthy individuals and patients with diabetes mellitus: a prospective cohort study.
    Br J Ophthalmol. 2024 Aug 28:bjo-2024-325515. doi: 10.1136/bjo-2024-325515.
    PubMed     Abstract available
    
    
    May 2024
14. ZHONG P, Yang S, Liu R, Zhu Z, et al
    Handgrip strength and risks of diabetic vascular complications: Evidence from Guangzhou Diabetic Eye Study and UK cohorts.
    Br J Ophthalmol. 2024 May 30:bjo-2023-324893. doi: 10.1136/bjo-2023-324893.
    PubMed     Abstract available
    
    
    
15. BRESSLER I, Aviv R, Margalit D, Rom Y, et al
    Autonomous screening for laser photocoagulation in fundus images using deep learning.
    Br J Ophthalmol. 2024;108:742-746.
    PubMed     Abstract available
    
    
    
16. JIN G, Ma Y, Zheng D, Jin L, et al
    Evaluation of systemic medications associated with diabetic retinopathy: a nested case-control study from the UK Biobank.
    Br J Ophthalmol. 2024 May 20:bjo-2023-324930. doi: 10.1136/bjo-2023-324930.
    PubMed     Abstract available
    
    
    
17. CHEONG KX, Zhang C, Tan TE, Fenner BJ, et al
    Comparing generative and retrieval-based chatbots in answering patient questions regarding age-related macular degeneration and diabetic retinopathy.
    Br J Ophthalmol. 2024 May 15:bjo-2023-324533. doi: 10.1136/bjo-2023-324533.
    PubMed     Abstract available
    
    
    
18. VINGOPOULOS F, Baldwin G, Katz R, Cui Y, et al
    Associations of quantitative contrast sensitivity with vascular metrics on widefield swept-source OCT angiography across stages of diabetic retinopathy.
    Br J Ophthalmol. 2024 May 6:bjo-2023-323900. doi: 10.1136/bjo-2023-323900.
    PubMed     Abstract available
    
    
    February 2024
19. MELLOR J, Jiang W, Fleming A, McGurnaghan SJ, et al
    Prediction of retinopathy progression using deep learning on retinal images within the Scottish screening programme.
    Br J Ophthalmol. 2024 Feb 5:bjo-2023-323400. doi: 10.1136/bjo-2023-323400.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.